Allink Biotherapeutics, a Beijing, China-based clinical-stage biotechnology company providing new bispecific antibody and antibody-drug conjugate (ADC) therapeutics, raised $42M in Series A funding.
The round was led by Lanchi Ventures, with participation from Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, alongside existing shareholders Gaorong Ventures and Med-Fine Capital.
The company intends to use the funds to advance:
- Global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies in Australia, the United States and China
- Enrichment of current portfolio by developing multiple highly competitive new assets in oncology and immunology
- Further development of its proprietary bispecific antibody and ADC technology platform
- Global footprint expansion
Led by Hui Feng, Ph.D., Founder and CEO, AllinkBio is a clinical stage biotechnology company leveraging its innovative proprietary platforms in bispecific antibodies and ADCs to develop a diverse pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. It aims to develop treatment paradigm shifting new drugs for patients in the oncology and immunology disease areas and address critical unmet medical needs globally.
FinSMEs
29/11/2024